Cagrilintide + Semaglutide (CagriSema) common uses, half-life, side effects and more

Semaglutide plus cagrilintide is an investigational weight-loss combination that pairs a GLP-1 receptor agonist with a long-acting amylin analogue in one weekly injection. The two act on different appetite hormones. The pairing aims to suppress hunger through both systems at once. It is studied for obesity and for type 2 diabetes with excess weight. The studied product is a fixed 1:1 combination that is not approved by any health authority in any country. People who buy it use gray-market blend vials or separate research vials of unverified identity, strength, and sterility. The semaglutide half is an approved prescription drug on its own. This exact combination is not.

• Weight loss in adults with obesity or overweight
• Blood sugar and weight control in type 2 diabetes with excess weight
• Appetite suppression through two gut-hormone pathways at once
• Gray-market metabolic stacks that copy the studied 1:1 combination

Once weekly

The studied target is 2.4 mg semaglutide plus 2.4 mg cagrilintide once weekly by subcutaneous injection. Both components step up together at a fixed 1:1 ratio. They start at 0.25 mg of each and rise every 4 weeks to the 2.4 mg target over about 16 weeks. Gray-market blend vials keep the 1:1 ratio and are sold mostly as 5 mg plus 5 mg. A 1:1 vial delivers equal milligrams of each drug. Drawing 2.4 mg of semaglutide from it also draws 2.4 mg of cagrilintide in the same shot. The blend has to be titrated up from a low start because the two doses cannot move apart.

• Read the vial label rather than the blend name because a CagriSema 10 mg vial holds 5 mg of each drug and one dose moves both together
• Separate vials let each drug be titrated on its own schedule rather than locked to the other

The blend has no single half-life because its two drugs clear separately. Semaglutide has a terminal half-life of about 1 week in humans. Cagrilintide falls between 159 and 195 hours. A coadministration study found the two do not change each other's clearance. Both support once-weekly dosing.

• Nausea, vomiting, diarrhea, constipation, reflux, or abdominal pain
• Appetite loss that can tip into under-eating, dehydration, or fatigue
• Injection-site redness, itching, bruising, swelling, or pain
• Headache, dizziness, weakness, or hair shedding during rapid weight loss
• Gallbladder problems, pancreatitis, or dehydration-related kidney injury can occur
• Low blood sugar becomes more likely with insulin or a sulfonylurea

• Semaglutide

  2.4 mg per weekly injection at the studied 1:1 target

• Cagrilintide

  2.4 mg per weekly injection at the studied 1:1 target, reached only by slow titration

Semaglutide activates the GLP-1 receptor. This raises insulin only when blood sugar is high, lowers glucagon on the same terms, slows stomach emptying, and reduces appetite through brain satiety pathways. Cagrilintide activates the amylin receptors and the calcitonin receptor. Amylin signaling drives fullness and cuts food intake mainly through the brainstem. The combination works on these two appetite systems at once. An early study reported a large drop in food intake on the combination. The two show no pharmacokinetic interaction. Whether their appetite effects fully add up in people is not yet mapped.

This exact combination has been tested directly in large phase 3 trials. REDEFINE 1 ran 68 weeks in 3,417 adults with obesity or overweight and no diabetes. It cut body weight by 20.4% against 3.0% on placebo and beat both semaglutide alone and cagrilintide alone. REDEFINE 2 tested the combination for 68 weeks in 1,206 adults with type 2 diabetes and excess weight. It lowered both body weight and blood sugar. These trials used a controlled dual-chamber injection rather than the gray-market vials people buy. Long-term cardiovascular outcomes and post-approval safety are not yet available. Gray-market blends and separate-vial stacks are not the studied product and carry the usual research-chemical purity, sterility, and dosing risks.

• A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 rules out use because the semaglutide component carries a thyroid C-cell tumor warning
• Matching a 1:1 blend to an already-high semaglutide dose delivers a full cagrilintide dose with no separate buildup and can bring on heavy nausea and vomiting
• Cagrilintide cannot be used in compounded medicines under United States federal law and gray-market vials can vary in identity, potency, sterility, and dose accuracy
• Pregnancy, breastfeeding, and trying to conceive are unsafe because cagrilintide caused fetal malformations in animals and semaglutide is stopped before a planned pregnancy
• Prior pancreatitis, gallbladder disease, severe gastroparesis, or repeated vomiting needs medical guidance before use
• Planned anesthesia or deep sedation needs procedure-team guidance because the GLP-1 component can leave food in the stomach and raise aspiration risk